Interventional device developer Boston Scientific of Natick, MA, has released financial results for its fiscal third quarter (end-September 30). For the period, the firm had net sales of $876 million, up 21% compared with $722 million reported for the third quarter of 2002. Net income for the quarter, excluding net special charges, was $137 million, an increase of 38% compared with $99 million, excluding net special credits, in the same period last year.
The net special charges for the quarter include purchased in-process research and development costs of $8 million (after tax) related to acquisitions, as well as $5 million in payments related to product liability settlements, the company said.
By AuntMinnie.com staff writersOctober 22, 2003
Related Reading
FDA sets date to review Boston Scientific stent, September 16, 2003
Boston Scientific releases Taxus clinical results, September 16, 2003
Boston Scientific’s Taxus stent receives Canadian approval, September 12, 2003
Boston Scientific, CryoVascular form alliance, September 11, 2003
Boston Scientific adds to IVUS offerings, August 14, 2003
Copyright © 2003 AuntMinnie.com
